Capricor Therapeutics, Inc. soars 450% on positive HOPE-3 DMD results. Discover market impact, growth potential, and risks.

Capricor Therapeutics shares gained after analysts said they believe the company can achieve profitability by 2028. The stock rose 8.4% to $29.14 and hit its 52-week high of $14.87 earlier in the ...

In 105 boys and young men enrolled in the HOPE-3 trial, patients given deramiocel every three months for a year had 54% ...

Piper Sandler raised the firm’s price target on Capricor Therapeutics (CAPR) to $45 from $20 and keeps an Overweight rating on the shares. The ...

Just last week, Shkreli had identified Capricor as his next major biotech short target, co-authoring a lengthy report and ...

Pivotal Phase 3 randomized, double-blind, placebo-controlled study (n=106) met the primary endpoint (PUL v2.0) and the key ...

Capricor shows positive HOPE-3 results with endpoints met, regulatory uncertainty, and a strong cash runway into 2026. Find ...

Turning to Wall Street, the analysts’ consensus rating for Capricor Therapeutics is Strong Buy, based on eight Buy ratings ...

Deramiocel, the lead product candidate, is still in late-stage development and has not yet received regulatory approvals, which raises concerns about the company's ability to bring products to market.

Capricor Therapeutics, Inc., (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics, today announced new data describing a scalable framework for loading ...

Capricor jumps after Phase 3 data show Deramiocel improves heart function and slows muscle decline in Duchenne muscular ...

Capricor is also harnessing the power of its exosome technology, using its proprietary StealthX™ platform in preclinical development focused on the areas of vaccinology, targeted delivery of ...